{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/amenorrhoea/management/secondary-amenorrhoea/","result":{"pageContext":{"chapter":{"id":"06391fac-7a04-5862-9279-2fea0c0708d9","slug":"secondary-amenorrhoea","fullItemName":"Scenario: Secondary amenorrhoea","depth":2,"htmlHeader":"<!-- begin field 6c30c7dd-598d-41e5-afcf-a78000d33589 --><h2>Scenario: Management of secondary amenorrhoea</h2><!-- end field 6c30c7dd-598d-41e5-afcf-a78000d33589 -->","summary":"Covers the management of secondary amenorrhoea.","htmlStringContent":"<!-- begin item f15a5c07-69ef-42fc-991a-a78000d333e5 --><!-- begin field 34bb9a46-9426-4668-b67b-acbc0158a5aa --><p>From age 13 years onwards (Female).</p><!-- end field 34bb9a46-9426-4668-b67b-acbc0158a5aa --><!-- end item f15a5c07-69ef-42fc-991a-a78000d333e5 -->","topic":{"id":"635ca828-9f27-5c84-b276-9a303cb30217","topicId":"968f93cb-fee3-4df5-83c2-a670cea5f458","topicName":"Amenorrhoea","slug":"amenorrhoea","lastRevised":"Last revised in August 2020","chapters":[{"id":"3084e6c6-7940-5e97-9fd1-ecb1526af0ec","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"05c35b63-85f8-528e-b16f-a5346f53c7af","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"ccc80bf0-145e-5a0b-a37c-5a33f15f2e2e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"6fdd6e3b-ed5e-5308-be10-14a6f09632b8","slug":"changes","fullItemName":"Changes"},{"id":"6c074480-101b-502d-b5a5-645e8620302d","slug":"update","fullItemName":"Update"}]},{"id":"3f4f9618-bd40-5219-8485-6bba1538b0d0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"6cebc623-7ec5-59d8-a838-972a8119c50e","slug":"goals","fullItemName":"Goals"},{"id":"f92a2577-5a88-5e7a-ab16-bf87344977a2","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"934ecd3e-77fb-5e9b-9698-5b74862da801","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"78664cf2-21cd-5b31-8d73-e7dc692120ea","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"749d6d4c-eb45-56e9-9b4d-62cc5798b9e0","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"9f7c349f-2f97-5b8a-b073-b638b6f43c0b","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9ca190f3-629d-57ca-8291-a3ea5b6121f9","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"04b120b8-de8f-59b5-a1bb-8104f57db04a","slug":"definition","fullItemName":"Definition"},{"id":"5d9e7439-6e78-51d2-a454-3a15abc5b4bb","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a96e50cf-494b-5f87-8a34-be56f2aff82e","slug":"causes","fullItemName":"Causes"},{"id":"923165de-ebc1-558d-bb85-61d331eccf9a","slug":"complications","fullItemName":"Complications"}]},{"id":"605ec635-9408-5c63-80f1-27cc6fb4abe3","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6e7a254f-f04a-5175-86cb-7edd443f7d08","slug":"when-to-suspect-primary-amenorrhoea","fullItemName":"When to suspect primary amenorrhoea"},{"id":"1acb9357-e5d7-5c08-9e96-f7969bbd443c","slug":"assessment-for-cause-primary-amenorrhoea","fullItemName":"Assessment for cause - primary amenorrhoea"},{"id":"14126b3e-6c95-50fe-bfe0-b6fa96c83f62","slug":"when-to-suspect-secondary-amenorrhoea","fullItemName":"When to suspect secondary amenorrhoea"},{"id":"837053aa-eb61-5825-9d01-6f1803d01484","slug":"assessment-for-cause-secondary-amenorrhoea","fullItemName":"Assessment for cause - secondary amenorrhoea"}]},{"id":"3588d9eb-4131-594c-819d-39bd1ff21ca3","fullItemName":"Management","slug":"management","subChapters":[{"id":"bbc8ee17-2dd5-5faf-af1a-c0d72235b826","slug":"primary-amenorrhoea","fullItemName":"Scenario: Primary amenorrhoea"},{"id":"06391fac-7a04-5862-9279-2fea0c0708d9","slug":"secondary-amenorrhoea","fullItemName":"Scenario: Secondary amenorrhoea"}]},{"id":"d2cba32a-a527-597d-901a-2337f2bd3492","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"516d0c94-b12d-53cd-b7b4-837a8b98697c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1a337663-3dd2-54df-b78d-676b1c9818ef","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"20d0143f-fdcf-5847-8aee-bf3d3a60b424","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"960991f6-3dae-54d7-bf3f-cb49e9e1adc8","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"45c9aa84-4b27-5a45-b280-415849c9af1d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2b117ca7-80c9-5ea2-b944-63dce78bd1ad","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bd8c3717-761d-5601-aad0-481c09055389","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"3588d9eb-4131-594c-819d-39bd1ff21ca3","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"9384e963-c0c5-5ffa-9ea3-7a03cf9acc67","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field d1a6661a-84d5-40c7-b18e-a78000d33592 --><h3>How should I manage secondary amenorrhoea?</h3><!-- end field d1a6661a-84d5-40c7-b18e-a78000d33592 -->","summary":null,"htmlStringContent":"<!-- begin item d6db265c-6f4a-4a9b-b2c5-a78000d3358e --><!-- begin field fc668b6b-dd27-490c-afd4-a78000d33592 --><ul><li><strong>Manage the following causes for secondary amenorrhoea in primary care:</strong><ul><li>Polycystic ovary syndrome (PCOS), when appropriate. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/polycystic-ovary-syndrome/\">Polycystic ovary syndrome</a> for more information.</li><li>Hypothyroidism (menses may take several months to resume with treatment). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypothyroidism/\">Hypothyroidism</a> for more information.</li><li>Menopause (women 40 years of age or older). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/menopause/\">Menopause</a> for more information.</li><li>Pregnancy. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/antenatal-care-uncomplicated-pregnancy/\">Antenatal care - uncomplicated pregnancy</a> for more information.</li></ul></li><li><strong>Refer all other people with secondary amenorrhoea for specialist investigation and, where appropriate, management of the </strong><a class=\"topic-reference internal-reference\" href=\"/topics/amenorrhoea/background-information/causes/#causes-of-secondary-amenorrhoea\">cause</a><strong>:</strong><ul><li><strong>Refer to a gynaecologist</strong> <strong>if she has any of the following:</strong><ul><li>Persistently elevated follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels, which suggests premature ovarian insufficiency in women younger than 40 years of age.</li><li>Recent history of uterine or cervical surgery (such as endometrial curettage, Caesarean section, or myomectomy) or severe pelvic infection (endometritis), which suggests Asherman's syndrome or cervical stenosis.</li><li>Infertility. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/infertility/\">Infertility</a> for more information.</li><li>Suspected PCOS, if diagnosis and management are not feasible in primary care. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/polycystic-ovary-syndrome/\">Polycystic ovary syndrome</a> for more information.</li></ul></li><li><strong>Refer to an endocrinologist</strong> <strong>if she has any of the following:</strong><ul><li>Hyperprolactinaemia: serum prolactin level greater than 1000 mIU/L, or 500–1000 mIU/L on two occasions. This includes those taking <a class=\"topic-reference internal-reference\" href=\"/topics/amenorrhoea/background-information/causes/#causes-of-secondary-amenorrhoea\">drugs that are known to increase prolactin levels</a>.</li><li>Low FSH and LH levels (to exclude hypopituitarism or a pituitary tumour, although stress, excessive exercise, or weight loss are more likely causes).</li><li>An increased testosterone level that is not explained by PCOS (suggesting an androgen-secreting tumour, late-onset congenital adrenal hyperplasia, or Cushing's syndrome).</li><li>Other features of Cushing's syndrome or late-onset congenital adrenal hyperplasia (besides an increased testosterone level).</li></ul></li></ul></li><li><strong>Manage amenorrhoea caused by weight loss, excessive exercise, stress, or chronic illness after an endocrinologist has assessed and excluded other hypothalamic or pituitary causes (such as a tumour). </strong><ul><li>For weight-related amenorrhoea, encourage weight gain and refer to a dietician if necessary. If an eating disorder is suspected, consider referral to a psychiatrist. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/eating-disorders/\">Eating disorders</a> for more information.</li><li>For exercise-related amenorrhoea, advise reducing exercise, increasing calorie intake, and weight gain. Consider referral to, or liaison with, a sports physician if available.</li><li>For stress-related amenorrhoea, consider measures to manage stress and improve coping strategies, such as cognitive behavioural therapy. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a>, <a class=\"topic-reference external-reference\" href=\"/topics/depression-in-children/\">Depression in children</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a> for more information.</li></ul></li><li><strong>Offer contraceptive advice</strong> to women who do not wish to become pregnant, as a small number of women with secondary amenorrhoea will become pregnant. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a> for more information.</li><li><strong>If amenorrhoea persists for more than 12 months, </strong>consider whether <a class=\"topic-reference internal-reference\" href=\"/topics/amenorrhoea/management/secondary-amenorrhoea/#managing-osteoporosis-risk\">osteoporosis prophylaxis</a> is required. </li></ul><!-- end field fc668b6b-dd27-490c-afd4-a78000d33592 --><!-- end item d6db265c-6f4a-4a9b-b2c5-a78000d3358e -->","subChapters":[{"id":"fb7fe8f1-1aaf-58e3-b852-fe78a8281aa8","slug":"basis-for-recommendation-5db","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b5c35580-ae4c-4ce1-a578-a78000d33592 --><h4>Basis for recommendation</h4><!-- end field b5c35580-ae4c-4ce1-a578-a78000d33592 -->","summary":null,"htmlStringContent":"<!-- begin item 5dbe1270-838c-441b-862a-a78000d33592 --><!-- begin field e6b634e9-f65f-4799-ba37-a78000d33592 --><h5>Primary care management of polycystic ovary syndrome (PCOS), hypothyroidism, menopause, and pregnancy</h5><ul><li>CKS recommends primary care management of those with PCOS, hypothyroidism, menopause, or pregnancy because it is normal clinical practice to manage these conditions in primary care.</li></ul><h5>Referral for specialist investigation to identify and treat the underlying cause of amenorrhoea</h5><ul><li>These recommendations are based on whether further investigation or treatment is needed in secondary care to identify and manage likely underlying causes of secondary amenorrhoea. Explicit recommendations on when to refer are lacking in the published literature, but most experts recommend referral if the underlying cause cannot be identified or if treatment can only be given in secondary care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Wilson et al, 2005</a>].</li><li><strong>Referral to a gynaecologist</strong><ul><li>Expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Ledger and Skull, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Practice Committee of the American Society for Reproductive Medicine, 2008</a>] and gynaecology textbooks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Balen, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Balen, 2004</a>] is that girls and women with suspected premature ovarian insufficiency (POI) should be referred for specialist assessment and management to enable:<ul><li>Confirmation of the diagnosis, which may include karyotyping in women younger than 30 years of age.</li><li>Treatment for infertility, if desired.</li><li>Monitoring and prophylaxis or treatment of osteoporosis.</li><li>Screening for other autoimmune disease (present in up to 40% of women); the most common is thyroiditis.</li></ul></li><li>Women with suspected Asherman's syndrome require hysteroscopy to confirm the diagnosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Balen, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Practice Committee of the American Society for Reproductive Medicine, 2008</a>].</li></ul></li><li><strong>Referral to an endocrinologist</strong><ul><li>The recommendation to refer to a specialist if the serum prolactin level is greater than 1000 mIU/L, or 500–1000 mIU/L on two occasions, is based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Wieck and Haddad, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Ledger and Skull, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Practice Committee of the American Society for Reproductive Medicine, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Heiman, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Klein, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Levy, 2014</a>] and a gynaecology textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Balen, 2004</a>], which states that persistent moderate elevations in prolactin levels warrant specialist investigation (usually magnetic resonance imaging [MRI] of the pituitary fossa) as it may be due to pituitary adenomas. </li><li>The recommendation to refer women with an increased testosterone level that is not explained by PCOS is based on the Royal College of Obstetricians and Gynaecologists (RCOG) guideline <em>Long-term Consequences of Polycystic Ovary Syndrome</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">RCOG, 2014</a>] and on expert opinion in a gynaecology textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Balen, 2012</a>], which recommend that an androgen-secreting tumour, late-onset congenital adrenal hyperplasia, and Cushing's syndrome should be excluded. This is likely to require secondary care expertise.</li><li>The recommendation to refer women with low follicle-stimulating hormone and luteinizing hormone levels to exclude hypopituitarism or a pituitary tumour is based on the expert opinions of several reviewers of this CKS topic.</li></ul></li></ul><h5>Managing amenorrhoea caused by weight loss, excessive exercise, stress, or chronic illness after assessment by an endocrinologist</h5><ul><li>The recommendation to manage hypothalamic amenorrhoea caused by weight loss, excessive exercise, stress, or chronic illness after assessment by an endocrinologist is based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Practice Committee of the American Society for Reproductive Medicine, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Heiman, 2009</a>] and gynaecology textbooks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Balen, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Rees, 2003</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Balen, 2012</a>], which states that a hypothalamic or pituitary tumour should be excluded before treating these conditions.</li><li>The recommendation to consider referring women who are underweight to a dietitian is based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">McIver et al, 1997</a>]. </li></ul><h5>Contraceptive advice</h5><ul><li>The recommendation to offer contraception to women who do not wish to become pregnant is based on evidence that women with POI have a 5–10% chance of natural conception, owing to intermittent ovarian function [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Balen, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Practice Committee of the American Society for Reproductive Medicine, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Heiman, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">ESHRE, 2015</a>].</li><li>The European Society of Human Reproduction and Embryology (ESHRE) recommends that women with POI should be advised to use contraception if they wish to avoid pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">ESHRE, 2015</a>].</li></ul><h5>Considering osteoporosis prophylaxis</h5><ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/amenorrhoea/management/secondary-amenorrhoea/#managing-osteoporosis-risk\">Managing osteoporotic risk</a> for more information.</li></ul><!-- end field e6b634e9-f65f-4799-ba37-a78000d33592 --><!-- end item 5dbe1270-838c-441b-862a-a78000d33592 -->","subChapters":[]}]},{"id":"cc2b5541-bc0f-531d-b5d5-ab272a99c904","slug":"managing-osteoporosis-risk","fullItemName":"Managing osteoporosis risk","depth":3,"htmlHeader":"<!-- begin field b8f852ae-e815-407e-a0bd-a78000d42263 --><h3>How should I manage the risk of osteoporosis?</h3><!-- end field b8f852ae-e815-407e-a0bd-a78000d42263 -->","summary":null,"htmlStringContent":"<!-- begin item 4815ea40-cd2d-491f-b50a-a78000d4211e --><!-- begin field f0924872-684a-42ca-8d44-a78000d42263 --><ul><li><strong>For women with premature ovarian failure (younger than 40 years of age), hypothalamic amenorrhoea, or hyperprolactinaemia </strong>(women with amenorrhoea associated with low oestrogen levels who are at increased risk of developing osteoporosis):<ul><li><strong>Treat the underlying cause,</strong> if possible.</li><li><strong>Assess their fragility fracture risk. </strong>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a>.</li><li><strong>Advise maintaining a healthy lifestyle </strong>to optimize bone health. This involves doing weight-bearing exercises, avoidance of smoking, eating a balanced diet, and maintenance of normal body weight. </li><li><strong>Correct vitamin D deficiency, and ensure an adequate calcium intake.</strong> See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/vitamin-d-deficiency-in-adults-treatment-prevention/\">Vitamin D deficiency in adults</a>.</li><li><strong>Consider offering hormone replacement therapy (HRT) or the combined oral contraceptive (COC) pill </strong>(both off-label use) if amenorrhoea persists for more than 12 months.<ul><li>Offer cyclical combined HRT (at the doses used for menopause) or a COC (if contraception is needed). See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/menopause/\">Menopause</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> for prescribing information.</li><li>Review treatment at least annually. For women with amenorrhoea due to reversible causes (such as weight loss or excessive exercise), oestrogen replacement should be periodically stopped (for example after 12 months of treatment, for 6 months) to see whether menses resumes off treatment.</li></ul></li><li><strong>If other pharmacological treatments, including bisphosphonates, are being considered,</strong> seek specialist advice.</li></ul></li></ul><!-- end field f0924872-684a-42ca-8d44-a78000d42263 --><!-- end item 4815ea40-cd2d-491f-b50a-a78000d4211e -->","subChapters":[{"id":"e9a93fe7-e050-5169-b99b-0840ebb080ec","slug":"basis-for-recommendation-678","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 296a509e-4f34-4f43-8de9-a78000d42267 --><h4>Basis for recommendation</h4><!-- end field 296a509e-4f34-4f43-8de9-a78000d42267 -->","summary":null,"htmlStringContent":"<!-- begin item 678d84b5-e756-4db9-8eb1-a78000d42267 --><!-- begin field fe0155e4-a70b-402a-8661-a78000d42267 --><h5>Identifying women at risk</h5><ul><li>Evidence from observational studies indicates that women with amenorrhoea associated with low oestrogen levels are at increased risk of osteoporosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Csermely et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Golden, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Balen, 2012</a>]. Expert opinion in the European Society of Human Reproduction and Embryology (ESHRE) guideline on <em>Management of women with premature ovarian insufficiency</em> is that the reduced bone mineral density (BMD) associated with premature ovarian insufficiency (POI) is very likely to indicate that POI is associated with an increased risk of fracture later in life, although this has not been adequately demonstrated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">ESHRE, 2015</a>]. </li></ul><h5>Treating the underlying cause</h5><ul><li>This recommendation is based on what CKS considers to be good clinical practice.</li></ul><h5>Advising on maintaining a healthy lifestyle, correcting vitamin D deficiency, and ensuring adequate calcium intake</h5><ul><li>These recommendations are extrapolated from the ESHRE guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">ESHRE, 2015</a>].</li></ul><h5>Hormone replacement therapy (HRT) and combined oral contraceptives (COC)</h5><ul><li>There is a consensus of expert opinion in a Cochrane systematic review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Marjoribanks, 2017</a>], review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Ledger and Skull, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Practice Committee of the American Society for Reproductive Medicine, 2008</a>], and gynaecology textbooks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Balen, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Balen, 2004</a>] that oestrogen replacement should be initiated to prevent excessive bone loss in women with hypothalamic amenorrhoea. In addition, the ESHRE recommends oestrogen replacement to maintain bone health and prevent osteoporosis in women with POI, stating that 'it is plausible that it will reduce the risk of fracture' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">ESHRE, 2015</a>].</li><li>There is no consensus on which (HRT or COCs) is preferable:<ul><li>Expert opinion in a review article is that the doses of oestrogen in HRT are insufficient to improve BMD in teenagers and young adults [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Hergenroeder, 1995</a>].</li><li>Expert opinion in a gynaecology textbook is that HRT is recommended (unless contraception is required) because of the lower oestrogen dose [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Balen, 2004</a>].</li></ul></li><li>The recommendation to periodically stop treatment is pragmatic and is based on a study of 93 women with hypothalamic amenorrhoea due to stress, exercise, or weight loss, in which more than 70% recovered some ovarian function over 8 years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Falsetti et al, 2002</a>].</li><li>Opinions in the published literature differ on the period of amenorrhoea after which oestrogen replacement is recommended, varying from 6–12 months [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Balen, 2000</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Balen, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Ledger and Skull, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">Practice Committee of the American Society for Reproductive Medicine, 2008</a>]. CKS recommends 12 months, to allow time for treatment of the underlying cause to be effective.</li></ul><h5>Considering other pharmacological treatments</h5><ul><li>This recommendation tis based on the ESHRE guideline, which states that other pharmacological treatments, including bisphosphonates, should only be considered with advice from a specialist [<a class=\"bibliography-reference internal-reference\" href=\"/topics/amenorrhoea/references/\">ESHRE, 2015</a>].</li></ul><!-- end field fe0155e4-a70b-402a-8661-a78000d42267 --><!-- end item 678d84b5-e756-4db9-8eb1-a78000d42267 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}